Abstract
Fenretinide or N-(4-hydroxyphenyl) retinamide (4HPR) is a synthetic retinoid currently being tested clinically, which can inhibit the development and the growth of breast and prostate cancers in rodents. The efficacy of 4HPR alone and in combination with cisplatin was tested against the human ovarian carcinoma IGROV-1 xenograft i.p. Administration p.o. of 4HPR was not effective, whereas intracavitary treatment significantly increased the survival time of treated mice. It also enhanced the antitumor activity of cisplatin. These findings suggest that 4HPR may be an active agent against epithelial ovarian tumors.
Footnotes
-
↵1 This work was supported in part by the Istituto Superiore della Sanità (Italy-USA Program on New Therapies of Neoplasia), by Associazione Italiana per la Ricerca sul Cancro and by Ministero della Sanità.
-
↵2 To whom requests for reprints should be addressed, at the Istituto Nazionale Tumori, Via Venezian 1, 20133 Milan, Italy.
- Received August 9, 1993.
- Accepted October 5, 1993.
- ©1993 American Association for Cancer Research.
Volume 53, Issue 22
